Of note, in a single-center retrospective analysis, the NSCLC patients with STK11/KRAS co-mutations (n = 36) exhibited longer OS on ICI treatment compared to the ones with STK11 mutation only (n = 37)30, inconsistent with the previous and our results12. Here, KRAS is linked to non-small cell lung carcinoma.